insights_auto
Outlook: 81.5% bullish·0.0% bearish
Go to analysischevron_right
LILY34:BVMF
Eli Lilly And Company BDR
R$260.48
arrow_upward
+0.37%(+0.97) 1D
Nov 4, 2:39:39 PM GMT-3 · BRL
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LILY34...
Open
R$263.00
High
R$263.88
Low
R$255.53
Mkt. cap
1.34T
Avg. vol.
48.37K
Volume
22.99K
52-wk high
R$263.88
52-wk low
R$141.70
Shares outstanding
940.75M
No. of employees
50K
Open
R$263.00
High
R$263.88
Low
R$255.53
Mkt. cap
1.34T
Avg. vol.
48.37K
Volume
22.99K
52-wk high
R$263.88
52-wk low
R$141.70
Shares outstanding
940.75M
No. of employees
50K
News stories
From web sources and news partners
Barron's
·
2 hours ago
Novo Nordisk Stock Shrugs Off Eli Lilly Threat as Weight-Loss Pill Shines in Earnings
Traders Union
·
3 hours ago
Eli Lilly stock weekly forecast: Support at $1,284 comes into focus after recent gains
Investor's Business Daily
·
3 hours ago
Novo Surges After Crushing Forecasts On The Back Of Its GLP-1s
Benzinga
·
4 hours ago
Why Is Novo Nordisk Stock Surging Wednesday? - Novo Nordisk (NYSE:NVO)
Profile
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
About Eli Lilly And Company BDR
CEODavid A. Ricks
Employees50K
Founded1876
HeadquartersIndianapolis, Indiana, United States
SectorPharmaceutical industry
Industry-
Websitelilly.com
Last report
Oct 29, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$7.48 / $6.35
+17.88%beat
arrow_upward
Revenue / Est. (USD)
24.40B / 22.62B
+7.88%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 19.29B | 19.80B | 22.97B | 24.40B |
Cost of goods sold | 3.37B | 3.58B | 3.27B | 3.93B |
Cost of revenue | 3.37B | 3.58B | 3.27B | 3.93B |
Research and development expenses | 3.80B | 3.51B | 3.82B | 4.25B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 3.46B | 2.93B | 3.43B | 3.12B |
Operating expense | 7.26B | 6.44B | 7.25B | 7.37B |
Total operating expenses | 10.63B | 10.02B | 10.52B | 11.30B |
Operating income | 8.66B | 9.78B | 12.46B | 13.09B |
Other non operating income | 181.20M | 170.00M | 561.00M | 13.00M |
EBT including unusual items | 8.27B | 8.85B | 9.25B | 8.41B |
EBT excluding unusual items | 8.89B | 9.71B | 12.73B | 12.89B |
Income tax expense | 1.63B | 1.45B | 2.15B | 1.96B |
Effective tax rate | 19.70% | 16.43% | 23.27% | 23.26% |
Other operating expenses | - | - | - | - |
Net income | 6.64B | 7.40B | 7.10B | 6.45B |
Net profit margin | 34.41% | 37.36% | 30.88% | 26.44% |
Earnings per share | 7.54 | 8.55 | 8.38 | 7.48 |
Interest and investment income | 672.40M | - | - | - |
Interest expense | -153.30M | -332.00M | -345.00M | -378.00M |
Net interest expenses | 519.10M | -332.00M | -345.00M | -378.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 9.25B | 10.29B | 12.99B | 13.64B |
Gain or loss from assets sale | -180.00M | - | - | - |
Upcoming events